# EDGAR Filing Document

**Accession Number:** 0000896747
**File Stem:** 0001654954-23-001846
**Filing Date:** 2023-2
**Character Count:** 6633
**Document Hash:** 97812b0678f8367c0d16f16cc6d6d969
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-001846.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0001654954-23-001846

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230215

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20230217

**DATE AS OF CHANGE**: 20230217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMERICAN BIO MEDICA CORP
- **CENTRAL INDEX KEY:** 0000896747
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 141702188
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-28666
- **FILM NUMBER:** 23640853

**BUSINESS ADDRESS:**
- **STREET 1:** 122 SMITH ROAD
- **CITY:** KINDERHOOK
- **STATE:** NY
- **ZIP:** 12106
- **BUSINESS PHONE:** 5187588158

**MAIL ADDRESS:**
- **STREET 1:** 122 SMITH ROAD
- **CITY:** KINDERHOOK
- **STATE:** NY
- **ZIP:** 12106

?xml version="1.0" encoding="utf-8"?abmc_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **<u>February 15, 2023</u>**

---

| |
|:---|
| **AMERICAN BIO MEDICA CORPORATION**  |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **New York** | **0-28666**  | **14-1702188**  |
| (State or other jurisdiction <br>of incorporation) | (Commission <br>File Number) | (IRS Employer <br>Identification Number) |

---

**<u>122 Smith Road, Kinderhook, NY 12106</u>**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **<u>518-758-8158</u>**

**<u>Not applicable</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s)  | Name of each exchange on which registered |
| Common | ABMC | OTC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On February 15, 2023, American Bio Medica Corporation (the "Company") held the 2023 Special Meeting of Shareholders (the "Special Meeting") at the Company's corporate offices in Kinderhook, New York, at which a quorum (27,863,899 shares of common stock of the 47,098,476 shares of common stock outstanding) was present in person or represented by proxy. The following is a brief description and vote count of all proposals voted on at the Special Meeting. The proposals voted on at the Special Meeting were described in detail in the Definitive Proxy Statement filed by the Company in connection with the Special Meeting.

**Proposal No. 1** – To consider and vote upon a proposal to approve the Asset Purchase Agreement, dated as of December 19, 2022, between the Company and Healgen Scientific Limited Liability Company for the Asset Sale of substantially all of ABMC's assets (the "Asset Sale"). The shareholders approved the Asset Sale, voting as follows:

---

| | | |
|:---|:---|:---|
| **For** | **Percent of Outstanding** | **Percent of Voted**  |
| 26381832 | 54.84% | 94.70 |

---

---

| | | |
|:---|:---|:---|
| **Against** | **Percent of Outstanding** | **Percent of Voted**  |
| 1476077 | 3.06% | 5.29% |

---

---

| | | |
|:---|:---|:---|
| **Withheld** | **Percent of Outstanding** | **Percent of Voted**  |
| 5990 | 0.01% | 0.02% |

---

There were no Broker Non-Votes regarding Proposal No. 1.

The approval of the Asset Sale required the affirmative vote of the holders of a majority of the outstanding shares of the Company's common stock (par value $0.01) that were present in person or represented by proxy at the Special Meeting.

**Proposal No. 2** - To grant authority to the Board of Directors of the Company (the "Board") to adjourn the Special Meeting, even if a quorum is present, if necessary or appropriate in the sole discretion of the Board, including to solicit additional proxies in the event that there are insufficient shares present in person or by proxy voting in favor of the Asset Sale. The shareholders voted as follows:

---

| | | |
|:---|:---|:---|
| **For** | **Percent of Outstanding** | **Percent of Voted**  |
| 22884882 | 47.57% | 82.25% |

---

---

| | | |
|:---|:---|:---|
| **Against** | **Percent of Outstanding** | **Percent of Voted**  |
| 4969877 | 10.33% | 17.84% |

---

---

| | | |
|:---|:---|:---|
| **Withheld** | **Percent of Outstanding** | **Percent of Voted**  |
| 9140 | 0.01% | 0.03% |

---

There were no Broker Non-Votes regarding Proposal No. 2.

There were no other matters voted upon or discussed at the Special Meeting other than the Proposals noted above.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | AMERICAN BIO MEDICA CORPORATION (Registrant) | AMERICAN BIO MEDICA CORPORATION (Registrant) |
| Dated: February 17, 2023  | By: | /s/ Melissa A. Waterhouse |
|  |  | Melissa A. Waterhouse |
|  |  | Chief Executive Officer (Principal Executive Officer) |
|  |  | Principal Financial Officer |

---